Abstract
Patients suffering from malignant brain tumours have an extremely poor prognosis (shorter than 15 months) irrespectively of improvements in surgergy, tumour imaging and therapeutic protocols. Brain tumour treatment has been principally hampered by poor permeability of drugs/therapeutics across the blood-brain barrier (BBB). Nanotechnology enabled treatments have shown unique promise in delivering drugs and macromolecules across the BBB and offer unique abilities in targeting tumour cells exploiting tumour biology, while also improving the pharmacokinetic profile of drugs and reducing off-target side-effects. In this chapter, we focus on the efficacy and safety of developed nano-enabled therapies that are currently under research for the treatment of brain tumours.
Original language | English |
---|---|
Title of host publication | Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors |
Editors | Prashant Kesharwani, Umesh Gupta |
Publisher | Elsevier |
Chapter | 5 |
Pages | 111-145 |
Number of pages | 35 |
Edition | 1st |
ISBN (Electronic) | 978-0128122495 |
ISBN (Print) | 978-0128122181 |
DOIs | |
Publication status | Published - 27 Apr 2018 |
Keywords
- Nanomedicines
- Drug conjugates
- Dendrimers
- Nucleic acid-based nanomedicines
- Peptide-based nanomedicines
- Polymeric nanoparticles
- Liposomes
- Glioblastoma Multiforme
- Brain tumours